Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Return on Equity (2021 - 2025)

Historic Return on Equity for TScan Therapeutics (TCRX) over the last 5 years, with Q3 2025 value amounting to 0.88%.

  • TScan Therapeutics' Return on Equity fell 4200.0% to 0.88% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.88%, marking a year-over-year decrease of 4200.0%. This contributed to the annual value of 0.65% for FY2024, which is 700.0% up from last year.
  • According to the latest figures from Q3 2025, TScan Therapeutics' Return on Equity is 0.88%, which was down 4200.0% from 0.7% recorded in Q2 2025.
  • TScan Therapeutics' Return on Equity's 5-year high stood at 0.61% during Q2 2021, with a 5-year trough of 0.88% in Q3 2025.
  • For the 5-year period, TScan Therapeutics' Return on Equity averaged around 0.51%, with its median value being 0.56% (2023).
  • Examining YoY changes over the last 5 years, TScan Therapeutics' Return on Equity showed a top increase of 2400bps in 2022 and a maximum decrease of -10500bps in 2022.
  • Over the past 5 years, TScan Therapeutics' Return on Equity (Quarter) stood at 0.29% in 2021, then crashed by -111bps to 0.61% in 2022, then increased by 9bps to 0.56% in 2023, then grew by 4bps to 0.54% in 2024, then crashed by -64bps to 0.88% in 2025.
  • Its Return on Equity was 0.88% in Q3 2025, compared to 0.7% in Q2 2025 and 0.58% in Q1 2025.